We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » DIA Annual Meeting: CBER Head Predicts Agency’s Guidance Process Will Be Changed by Pandemic
DIA Annual Meeting: CBER Head Predicts Agency’s Guidance Process Will Be Changed by Pandemic
The FDA has been forced to streamline its guidance development process during the COVID-19 pandemic, and the change is likely to shape its approach beyond the pandemic, says Center for Biologics Evaluation and Research (CBER) Director Peter Marks.